Skip to content
Clinical Trials – home

Hospital Universitario Virgen De Las Nieves

Research site

Spain Avenida De Las Fuerzas Armadas 2, 18014 Granada, Spain

  • 88 trials recruiting
  • Hidradenitis · Breast cancer · Dermatitis atopic
  • Adults and children

About Specializations

Hospital Universitario Virgen De Las Nieves in Granada, Spain specialises in clinical trials of conditions such as Hidradenitis, Breast cancer, Dermatitis atopic, Chronic obstructive pulmonary disease, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology and Hematologic Malignancies

The Hospital Universitario Virgen De Las Nieves in Granada is highly active in neoplasms and blood cancers, with studies focused on diseases such as breast cancer, ovarian cancer, lung cancer, prostate cancer, bladder cancer, multiple myeloma, and lymphomas. The research is largely aimed at improving treatment effectiveness, comparing new combinations, and supporting better disease control in both early and advanced settings.

  • Testing new treatment approaches for advanced and early-stage breast cancer, including hormone receptor-positive and HER2-related disease
  • Evaluating therapies for multiple myeloma, myelodysplastic syndromes, and other hematologic cancers
  • Studying targeted and immunotherapy-based options for lung cancer, bladder cancer, and prostate cancer

Many of these trials explore whether newer oncology strategies can improve survival, reduce recurrence, or offer better options after standard treatment has already been used.

Respiratory, Allergy, and Immune-Mediated Disease Research

Research at this site also covers respiratory diseases, immune system diseases, and allergic conditions, including asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, eosinophilic granulomatosis with polyangiitis, and urticaria. The trials are designed to assess symptom control, long-term safety, and the effectiveness of targeted therapies in chronic inflammatory disease.

  • Improving treatment for asthma, including eosinophilic and difficult-to-control forms
  • Studying advanced care for COPD and progressive fibrosing interstitial lung disease
  • Evaluating therapies for atopic dermatitis, hidradenitis suppurativa, and other immune-driven skin conditions

These studies aim to help people with long-term inflammatory disorders achieve better symptom relief and more durable disease control.

Cardiovascular, Kidney, and Metabolic Medicine

The site conducts clinical research in cardiovascular diseases, kidney disorders, and metabolic disease, including hypertension, heart failure, cardiomyopathy, spontaneous coronary artery dissection, chronic kidney disease, and type 2 diabetes. These trials often focus on whether new treatments can improve organ function, lower risk, or better manage complex chronic illness.

  • Assessing therapies for heart failure, hypertrophic cardiomyopathy, and other cardiac conditions
  • Studying treatment options for resistant hypertension and vascular complications
  • Evaluating kidney-focused research in delayed graft function, focal segmental glomerulosclerosis, and Alport syndrome

This area reflects a strong interest in improving outcomes for patients with overlapping heart, kidney, and metabolic risks.

Neurology, Psychiatry, and Pain Studies

Clinical trials in nervous system diseases and mental disorders include research on epilepsy, Parkinson’s disease, Alzheimer’s disease, glioblastoma-related neurological disease, and major depressive disorder. The research also includes studies of chronic pain, with an emphasis on improving symptom relief and daily functioning.

  • Testing new options for focal epilepsy and seizure control
  • Exploring treatments for early Parkinson’s disease and Alzheimer’s disease
  • Evaluating approaches for chronic low back pain and depression with anhedonia

At Hospital Universitario Virgen De Las Nieves, these studies are aimed at helping patients manage persistent neurological symptoms with more effective and better-tolerated care.

Infectious Diseases, Transplantation, and Hematologic Support

A substantial part of the research portfolio addresses bacterial infections, viral disease, HIV infection, and transplant-related complications. Trials include studies in sepsis, bacteremia, infective endocarditis, acute graft-versus-host disease, and transplant-associated complications, with the goal of improving infection control and post-transplant recovery.

  • Evaluating better treatment strategies for septic shock and severe bloodstream infections
  • Studying supportive care after kidney transplantation, liver transplantation, and stem cell transplantation
  • Investigating prevention and treatment of graft-versus-host disease and related immune complications

These trials focus on safer infection management and improved outcomes for patients undergoing high-risk medical and surgical care.

Dermatology, Ophthalmology, and Reconstructive Care

The site also supports research in skin and connective tissue diseases and eye diseases, including psoriasis, atopic dermatitis, hidradenitis suppurativa, actinic keratosis, corneal ulcers, and thyroid eye disease. These studies are designed to improve symptom control, tissue healing, and long-term safety of treatment.

  • Testing new therapies for psoriasis and other chronic inflammatory skin conditions
  • Evaluating treatments for corneal disease and severe ocular surface damage
  • Studying reconstructive approaches for skin cancer and wound repair

The research in this field combines symptom management with efforts to improve recovery and quality of life for patients with chronic dermatologic and eye conditions.

Gastroenterology, Liver Disease, and Other Internal Medicine Studies

As a major Interna department research center, the site includes studies in digestive system diseases, liver disease, and metabolic disorders, such as acute pancreatitis, hepatocellular carcinoma, and post-gastrectomy or pancreatic insufficiency-related care. The purpose is often to compare supportive treatments, improve recovery, or refine care for complex internal medicine patients.

  • Assessing treatment strategies for acute pancreatitis and related complications
  • Studying liver-directed and immunotherapy-based approaches for hepatocellular carcinoma
  • Exploring care needs after major gastrointestinal surgery and in nutritional and metabolic disease

These investigations reflect broad internal medicine research that connects organ-specific disease care with overall patient stability and recovery.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Avenida De Las Fuerzas Armadas 218014 GranadaSpain
Recruiting now
88 trials
Conditions studied
187

More sites in GranadaSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

264 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
  • Sponsor:Novo Nordisk A/S

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:PF-07275315
  • Sponsor:Pfizer Inc.

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Renal disorder

Recruiting

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Summit Therapeutics Inc.

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of Nadofaragene Firadenovec for Adults with Intermediate Risk Non-Muscle Invasive Bladder Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nadofaragene firadenovec
  • Sponsor:Ferring Pharmaceuticals A/S
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.